Genetically determined debrisoquine oxidation capacity in bladder cancer.
A report is given of a series of bladder cancer cases examined for the oxidation capacity demonstrated by the use of debrisoquine. No overall association of poor and extensive metaboliser exists between bladder cancer patients and a control group. An absolute association between a benzidine exposed subgroup and metaboliser status exists, but the numbers are too small to indicate the true nature of this relationship.
D001560:Benzidines / Q000633:toxicity; D003647:Debrisoquin / Q000378:metabolism*; D006801:Humans; D007546:Isoquinolines / Q000378:metabolism*; D009784:Occupational Diseases / Q000378:metabolism; D010084:Oxidation-Reduction; D001749:Urinary Bladder Neoplasms / Q000209:etiology / Q000378:metabolism*
D001560:Benzidines; D007546:Isoquinolines; D003647:Debrisoquin